{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:16Z","timestamp":1792597096778,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ecl.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:26:14Z","timestamp":1787948774000},"page":"599-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Perimenopausal Bone Loss"],"prefix":"10.1016","volume":"55","author":[{"given":"Michael R.","family":"McClung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2026.07.001_bib1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/jc.2011-3362","article-title":"Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"97","author":"Harlow","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib2","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1359\/jbmr.2000.15.10.1965","article-title":"Characterization of perimenopausal bone loss: a prospective study","volume":"15","author":"Recker","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the study of Women\u2019s Health across the Nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1701-2163(15)30410-2","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density","volume":"36","author":"Khan","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.ecl.2026.07.001_bib5","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s001980050066","article-title":"A prospective study of bone loss in menopausal Australian-born women","volume":"8","author":"Guthrie","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2026.07.001_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF00310195","article-title":"The effects of menopause on longitudinal bone loss from the spine","volume":"52","author":"Pouilles","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ecl.2026.07.001_bib15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0149-2918(98)80075-1","article-title":"Evidence that increased calcium intake does not prevent early postmenopausal bone loss","volume":"20","author":"Hosking","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.ecl.2026.07.001_bib32","first-page":"711","article-title":"Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis","volume":"101","author":"Luckey","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2026.07.001_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bone.2008.09.011","article-title":"Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss","volume":"44","author":"McClung","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2026.07.001_bib35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2026.07.001_bib40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00774-025-01670-3","article-title":"Efficacy of zoledronic acid in peri-menopausal women with osteopenia","volume":"44","author":"Prasad","year":"2026","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2026.07.001_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.gme.0000184425.73567.12","article-title":"Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects","volume":"12","author":"Greenwald","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2026.07.001_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(99)00076-9","article-title":"A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group","volume":"24","author":"Delmas","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2026.07.001_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bone.2017.12.016","article-title":"Perimenopausal bone histomorphometry before and after menopause","volume":"108","author":"Recker","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2026.07.001_bib10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-002-2104-4","article-title":"Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography","volume":"73","author":"Dufresne","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ecl.2026.07.001_bib11","doi-asserted-by":"crossref","first-page":"e1872","DOI":"10.1210\/clinem\/dgz056","article-title":"Trabecular bone score declines during the menopause transition: the study of Women\u2019s Health Across the Nation (SWAN)","volume":"105","author":"Greendale","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"405","key":"10.1016\/j.ecl.2026.07.001_bib12","first-page":"1","article-title":"Osteoporosis or low bone mass in older adults: United States, 2017-2018","author":"Sarafrazi","year":"2021","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.ecl.2026.07.001_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11657-023-01292-0","article-title":"A clinical prediction model for 10-year risk of self-reported osteoporosis diagnosis in pre- and perimenopausal women","volume":"18","author":"Zeitlin","year":"2023","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.ecl.2026.07.001_bib14","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1530\/JOE-16-0089","article-title":"Influence of body weight on bone mass, architecture and turnover","volume":"230","author":"Iwaniec","year":"2016","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ecl.2026.07.001_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/oxfordjournals.aje.a117362","article-title":"Lifetime leisure exercise and osteoporosis. The Rancho Bernardo study","volume":"141","author":"Greendale","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ecl.2026.07.001_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117650","article-title":"Does exercising during peri- or early post-menopause prevent bone and muscle loss: a systematic review","volume":"201","author":"Whitman","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2026.07.001_bib20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2026.07.001_bib22","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2026.07.001_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women\u2019s Health Initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/aje\/kwaa210","article-title":"Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age","volume":"190","author":"Prentice","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ecl.2026.07.001_bib25","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s00198-022-06483-y","article-title":"Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women\u2019s Health Initiative hormone therapy trials","volume":"33","author":"Lorentzon","year":"2022","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2026.07.001_bib26","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1067\/mob.2001.116525","article-title":"Oral contraceptive use in perimenopause","volume":"185","author":"Kaunitz","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ecl.2026.07.001_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00024677-200403030-00006","article-title":"Effects of oral contraceptives on bone mineral density","volume":"3","author":"Gambacciani","year":"2004","journal-title":"Treat Endocrinol"},{"key":"10.1016\/j.ecl.2026.07.001_bib28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ecl.2026.07.001_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ph18071068","article-title":"Bisphosphonates in the management of patients with postmenopausal osteoporosis; back to the future","volume":"18","author":"Papapoulos","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ecl.2026.07.001_bib36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","article-title":"Alendronate in the prevention of osteoporosis: 7-year follow-up","volume":"15","author":"Sambrook","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2026.07.001_bib37","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","article-title":"Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort study","volume":"89","author":"McClung","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib39","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1210\/clinem\/dgaf569","article-title":"Antifracture efficacy of 5- or 10-yearly zoledronate in women aged 50 to 60 years: secondary analyses of a randomized trial","volume":"111","author":"Bolland","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib42","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2026.07.001_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2026.07.001_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jbmr.4802","article-title":"Effect of a three-day course of dexamethasone on acute phase response following treatment with zoledronate: a randomized controlled trial","volume":"38","author":"Murdoch","year":"2023","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib46","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib48","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/clinem\/dgac636","article-title":"Comparisons between different anti-osteoporosis medications on postfracture mortality: a population-based study","volume":"108","author":"Wu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.11005\/jbm.25.933","article-title":"Bisphosphonate use and reduced all-cause mortality in Korean women older than 50 years: a nationwide cohort study","volume":"32","author":"Park","year":"2025","journal-title":"J Bone Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib50","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ecl.2026.07.001_bib51","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/GME.0000000000001393","article-title":"Improved periodontal disease and prevention of tooth loss in osteoporosis patients receiving once-yearly zoledronic acid: a randomized clinical trial","volume":"26","author":"Taguchi","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2026.07.001_bib52","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib54","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/jbmr\/zjag070","article-title":"Asian ethnicity is associated with shorter anti-resorptive exposure prior to atypical femur fracture (AFF): a Transcontinental Atypical Femoral Fracture Consortium (TrAFFiC) cohort study","author":"Collins","year":"2026","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib56","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJMc1403799","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"371","author":"Schilcher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib57","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib58","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ecl.2026.07.001_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","article-title":"Sequential and long-term therapy for osteoporosis","volume":"23","author":"McClung","year":"2025","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.ecl.2026.07.001_bib60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ecl.2026.07.001_bib61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2026.07.001_bib62","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2026.07.001_bib63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2026.07.001_bib64","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2026.07.001_bib65","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate\/Estrogen Study Group","volume":"85","author":"Bone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib66","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.001_bib67","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/GME.0b013e31827b24af","article-title":"Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial","volume":"20","author":"Min","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2026.07.001_bib68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.ogx.0000189152.95070.f8","article-title":"Skeletal consequences of hormone therapy discontinuance: a systematic review","volume":"61","author":"Simon","year":"2006","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ecl.2026.07.001_bib69","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","article-title":"Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin","volume":"299","author":"Heiss","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2026.07.001_bib70","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib71","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"key":"10.1016\/j.ecl.2026.07.001_bib72","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2026.07.001_bib73","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.001_bib74","doi-asserted-by":"crossref","first-page":"e2491","DOI":"10.1210\/clinem\/dgab279","article-title":"Faster lumbar spine bone loss in midlife predicts subsequent fracture independent of starting bone mineral density","volume":"106","author":"Shieh","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.07.001_bib75","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jama.2024.27154","article-title":"Screening for osteoporosis to prevent fractures. US preventive services task force recommendation statement","volume":"333","year":"2025","journal-title":"JAMA"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:15Z","timestamp":1792593615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0889852926000575"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.07.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Perimenopausal Bone Loss","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}